160 results about "Nervous system disease" patented technology

The invention discloses a nervous system disease auxiliary evaluation method based on a large model and related equipment. The method comprises the following steps: constructing a structured knowledge graph based on multi-modal heterogeneous data of nervous system disease guide texts, symptom descriptions and examination results; a graph neural network module is embedded based on the structured knowledge graph in combination with a large language model, an inference network model of a dynamic graph structure is generated, and a dynamic diagnosis path tree is formed by calculating the relation weight between the medical nodes in the graph; and generating interpretable diagnosis suggestions through the reasoning network model according to the current symptom description, the examination result and the historical medical history of the patient. The problems that an existing model still has obvious bottlenecks and clinical challenges, depends on single modal data, is insufficient in quantification of dynamic signs such as a reasoning level, tremor frequency and gait abnormity, does not achieve disease development time sequence modeling and is difficult in clinical conversion can be solved.

The invention discloses application of a propanamide derivative in preparation of a medicine for treating nervous system diseases, and belongs to the technical field of medicines, and the propanamide derivative is N-[(6-methoxy-1H-benzimidazole-2-yl) methyl]-3-(pyridine-3-yl) propanamide. The invention discloses the neuroprotection application of the propanamide derivative for the first time by adopting the propanamide derivative to prepare a medicine for treating nervous system diseases, and the protection efficacy of the propanamide derivative is equivalent to that of a positive medicine MK-801.

1. The name of the design product: ultrasonic therapeutic instrument. 2. The use of the design product: for the auxiliary treatment of cardiovascular and cerebrovascular diseases, soft tissue contusion, and nervous system disease rehabilitation. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: perspective view 1.

To provide a method for treating a GLP-1 / GLP-1 1R related disease such as a carbohydrate metabolism disorder-related disease, a fat metabolism disorder-related disease, or a GLP-1 / GLP-1 1R related nervous system disease, and to provide a medicament.SOLUTION: Provided is a method for treating a disease by regulating GLP-1 / GLP-1 1R, comprising administering an effective amount of GLP-1 to a subject.SELECTED DRAWING: None

The invention discloses a construction method of a conditional knock-down dynactin animal model of astrocytes and an application of the animal model of the conditional knock-down dynactin animal model of the astrocytes. According to the method, a Dctn1LoxP gene knock-in mouse is hybridized with an Aldh1l1-Cre / ERT2 transgenic mouse, a target genotype mouse is obtained through three rounds of breeding, 100mg / kg Tamoxifen is continuously injected into the intraperitoneal cavity of the 2-month-old mouse for 5 days, and specific knock-down of dynactin in brain and spinal astrocytes is realized, including knockout of p150Glue and reduction of DCTN4, p50 and Arp1alpha protein levels. The model has the advantages of being high in specificity, permanent in intervention aging and capable of covering multiple life stages, the defects of a traditional model are overcome, the model can be used for researching the influence of dynactin on astrocyte neurobiological functions, a reliable tool is provided for screening related targets of nervous system diseases, and the model has important application value.

This invention relates to the field of pharmaceutical science, and more particularly to the application of NAT10 antagonists in the preparation of medicaments for the prevention and / or treatment of epilepsy. This invention provides the application of NAT10 antagonists in the preparation of medicaments for the prevention and / or treatment of neurological diseases characterized by epileptic seizures. This invention is the first to demonstrate through pharmacological experiments that a NAT10 antagonist, remodelin, has anti-epileptic effects, thus possessing high clinical application value and development prospects.

The invention provides a construction method and application of a humanized MECP2 gene mouse model, and relates to the field of gene engineering. The model animal with the humanized hMECP2 gene is successfully prepared, the humanized hMECP2 protein can be normally expressed in the body of the model, and the model can be used for MECP2 gene function research and screening and evaluation of human MECP2 targeted drugs and therapies. The animal model prepared by the invention can be used for rapidly establishing more different MECP2 mutation humanized disease mouse models, and is applied to drug screening, drug effect research, related nervous system disease and tumor treatment and the like aiming at human MECP2 target sites, so that the research and development process of new drugs is accelerated, the time and the cost are saved, and the drug development risk is reduced. And a powerful tool is provided for researching the functions of the MECP2 protein and screening drugs.

This invention discloses an alkaloid compound and its uses. Specifically, the invention relates to compounds of formula (I), or stereoisomers, tautomers, nitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts, or prodrugs of compounds of formula (I), and also to pharmaceutical compositions comprising said compounds and their uses. In particular, this alkaloid compound has a significant inhibitory effect on angiogenesis and can be used as a medicament for the prevention or treatment of tumors, inflammation, ophthalmic diseases, abnormal fibrosis or scar formation, cardiovascular and cerebrovascular diseases, nervous system diseases, infectious diseases, metabolic diseases, and diseases related to abnormal angiogenesis in mammals.

The present invention addresses the problem of providing a suppressant for nervous system vascular barrier breakdown. Provided is a suppressant for nervous system vascular barrier breakdown, the suppressant comprising (a) or (b) as an active ingredient: (a) an enzyme capable of specifically detaching or decomposing a sugar chain of low-glycosylated basigin; and (b) an antibody, an aptamer, or a lectin that specifically binds to low-glycosylated basigin and suppresses the nervous system vascular barrier breakdown caused by basigin.　Preferably, the sugar chain of the low-glycosylated basigin is high-mannose sugar chain.

The present invention relates to polymorphs of a nitrogen-containing heterocyclic compound. The polymorphs of the present invention can effectively enhance or reactivate synaptic plasticity, and inhibit or eliminate the accumulation of beta-amyloid, without causing side effects, thereby exerting a therapeutic effect on various nervous system diseases or neurodegenerative diseases. In addition, the polymorphs of the present invention exhibit excellent physicochemical properties, such as stability, solubility, hygroscopicity, and mechanical strength, and show excellent permeability to the blood-brain barrier (BBB).

The utility model relates to a detection kit of autoimmune nervous system disease, including box and with box rotation connection's box cover, the inside position adjustable of box is provided with a plurality of baffle, the both sides of each baffle upper portion respectively symmetry is provided with a plurality of clamping block, moves the baffle, makes the clamping block between adjacent two baffles clamp test tube, each baffle top is equipped with the limiting structure for fixing its position, the inside one side of box evenly interval is provided with a plurality of card slot, the baffle one side has opened first recess, and the baffle upside has opened the second recess with first recess intercommunication, the limiting structure includes the clamping block for with first recess sliding fit and with clamping block vertical connection's operating block, the operating block is away from the inner wall between second recess between clamping block one side and first recess and is equipped with the compression spring. The detection kit of autoimmune nervous system disease can clamp test tube of different diameter size, and the scope of application is wider.

The invention discloses a sparse electroencephalogram signal source positioning method based on functional magnetic resonance guidance, and relates to the crossing field of electroencephalogram signal processing and neuroimaging technologies. The method mainly comprises three parts of fMRI-guided sparse source space construction, subject specificity forward model construction and multi-target regularization inverse problem solving. The method comprises the following steps: firstly, screening high-activation voxels through BOLD signal intensity of fMRI, and constructing a sparse source space through connected component analysis and representative point selection; then, a subject specific boundary element (BEM) head model is constructed based on the structural MRI, and electrode registration and lead field matrix calculation are completed; and then a multi-target regularization model fusing data fidelity, space compactness and intensity consistency is constructed, optimal estimation of source current intensity is obtained through analysis and solution, and finally a positioning result of brain power activation is output. According to the method, the advantages of high time resolution of the EEG and high spatial resolution of the fMRI are fully played, the limitations of inverse problem morbidity, low spatial resolution and insufficient multi-mode fusion in traditional brain power supply positioning are effectively solved, and brain power supply positioning with high precision, noise resistance and high interpretability is realized; and a new scheme is provided for cognitive neuroscience research, nervous system disease diagnosis and brain-computer interface development.

The present disclosure provides compounds, such as compounds of Formula I, and their use in the treatment of medical diseases or disorders, such as psychiatric and nervous system diseases. Pharmaceutical compositions and methods of making various benzisoxazole and benzisothiazole compounds are provided. These compounds are considered to be modulators of the serotonin 2A (5-HT2A) receptor.

Provided herein are bilobalide derivative compounds, processes for their preparation, methods of use, and uses for the prevention or treatment of nervous system diseases and cancer.

The present invention relates to a steroid derivative regulator, in particular to a compound of formula (I), a salt and crystal form thereof, a preparation method therefor, a pharmaceutical composition containing a therapeutically effective amount of the crystal form, and an application thereof as a GABAA receptor regulator in treatment of depression, convulsions, Parkinsonism and nervous system diseases.

The invention provides a method for preventing or treating diseases related to CSNK2B gene deletion. The disclosure also provides a CSNK2B protein or a variant thereof, a nucleic acid molecule encoding a CSNK2B protein or a variant thereof, an expression cassette comprising a nucleic acid molecule encoding a CSNK2B protein or a variant thereof, a vector comprising a nucleic acid molecule encoding a CSNK2B protein or a variant thereof, a virus, such as an AAV particle, expressing a CSNK2B protein or a variant thereof, and a method for preparing the CSNK2B protein or a variant thereof. According to the present invention, the use of the cells expressing the CSNK2B protein in the preparation of drugs for treating or preventing CSNK2B gene deletion-related diseases in subjects is provided, and the CSNK2B gene deletion-related diseases are selected from the group consisting of Rett syndrome, autism spectrum disorder (ASD), Porier-Bienvenu neurodevelopment syndrome (POBINDS), epilepsy or broad-spectrum development retardation, or the use of the cells expressing the CSNK2B protein in the preparation of the drugs for treating or preventing the CSNK2B gene deletion-related diseases in the subjects,

The invention discloses application of a Kunlun chrysanthemum aqueous extract in preparation of drugs for improving autism core symptoms, and belongs to the technical field of biological medicines. In order to solve the problem that the prior art lacks a medicine which is small in side effect, natural in source and capable of improving the autism core symptom, the invention provides application of a coreopsis tinctoria aqueous extract in preparation of the medicine for improving the autism core symptom, and the coreopsis tinctoria aqueous extract has a multi-dimensional synergistic effect of adjusting synaptic plasticity, inhibiting neuroinflammation, improving behavioral phenotype and the like. The concept of treating complex nervous system diseases by traditional Chinese medicine is met, and the autism core symptom is fundamentally improved; the medicine containing the coreopsis tinctoria aqueous extract provided by the invention has the advantages of high safety and small side effect.

The invention belongs to the technical field of biology, and particularly relates to a construction method of a respiratory syncytial virus infected mouse model. Disodium clodronate liposome with the concentration of 4ng / mL is injected into the lateral ventricle of the mouse through stereotactic positioning of the brain. 48h after injection, mouse brain tissues are taken to detect the activation state of microglial cells through immunofluorescence and WB, after it is confirmed that the microglial cells are inhibited, RSV (virus titer: 2.8 * 10 < 6 > PFU) nasal drop infection experiments are carried out on the mouse, and after the 5th day after virus infection, the mouse is infected by the RSV (virus titer: 2.8 * 10 < 6 > PFU) nasal drop infection experiments. Likewise, mouse brain tissue is taken for virus load detection, and neuropathological changes of the mouse brain tissue are observed through HE staining, immunofluorescence and TUNEL staining, so that the method can be used for constructing a research model of RSV-related nervous system diseases.

The present application describes small molecule OGG1 modulators, processes for the preparation of these compounds, and the effects of these compounds on the enzymatic and functional activity of OGG1. The method further comprises treating a variety of diseases, including cancer, cardiovascular disease, nervous system disease, inflammatory disease, autoimmune disease, and infectious disease.

This invention relates to bacterial strains of the genus Lactiplantibacillus or a mixture thereof for use in preventing and / or treating a nervous system disease in a subject in need thereof. This invention also relates to compositions comprising bacterial strain of the genus Lactiplantibacillus or a mixture thereof for use in preventing and / or treating a nervous system disease in a subject in need thereof.

Antibodies that specifically bind to TrkB and methods for using the same are described. Neuroprotective agonist antibodies are described, as indicated by their effect on enhancing the survival of retinal ganglion cells in vitro, and these agonist antibodies may be used to treat eye disorders, such as glaucoma. Additionally, other neuronal diseases or disorders, including those characterized by partial neuronal damage, benefit from treatment using these agonist antibodies. In certain embodiments, the present invention comprises antibodies that bind to TrkB and mediate cell signaling. The antibodies of the present invention may be whole human, non-natural antibodies formulated as injectable excipients.

The present invention relates to a compound of formula (I), a compound-linker construct comprising the compound, and a conjugate comprising the compound-linker and a targeting moiety. The compound of the present invention has the ability to stimulate and / or induce, particularly induce degradation of a target protein. Such a target protein may be a protein involved in diseases, like cancer, metabolic disorder, infectious disease and / or neurological disorder, namely in particular cyclin K (CCNK) and / or CDK12 and / or CDK13. The present invention also relates to the compound, the compound-linker construct and the conjugate for use as medicament, preferably for use in treating specific diseases as disclosed herein.

The invention provides an application of a zanthoxylum amide compound in preparation of a medicine for preventing and / or treating nervous system diseases related to hypoxia neuroinflammation. The zanthoxylum amide compound disclosed by the invention has the following structure.

Provided are a reblastatin derivative and use thereof in neurological diseases. Modifying the hydroxyl group at position 18 of reblastatin improves the therapeutic activity on the nervous system. In addition, especially when the hydroxyl group is replaced with a methyl group, the lipid solubility of the compound can be improved, thereby improving the brain penetration efficiency.

The application relates to application of a furan coumarin compound shown in a formula I to prevention and / or treatment of a nervous system disease related to neuroinflammation. The furan coumarin compound has a protective effect on normoxia + lipopolysaccharide (LPS) and hypoxia + LPS combined induction of mouse stellate glial C8-D1A cell normoxia and hypoxia neuroinflammation models, can promote cell growth, inhibit production of related inflammatory factors, effectively reduce brain water content production, weight loss and key protein expression of a plateau cerebral edema model mouse, and can be developed into a medicine for preventing and / or treating neuroinflammation related diseases.

This invention relates to the field of natural language processing technology, specifically to a triage method and system for neurological diseases, comprising the following steps: segmenting the syntactic structure of the patient's chief complaint text sequence and identifying nodes; calculating and quantifying the nesting degree of the patient's linguistic organization logic; and obtaining a syntactic potential depth value. This invention can filter out noise interference from complex clinical expressions and extract neurological syndrome features by comparing them with a preset internal capsule lesion pattern. By jointly analyzing feature tensors pointing to limb paralysis with syntactic potential depth values ​​below the normal threshold, dual cross-validation of somatic motor disorders and central cognitive impairment is achieved. Furthermore, by comparing with feature thresholds of peripheral nerve or spinal cord lesions, the specificity of identifying central acute and severe illnesses such as ischemic stroke is improved, optimizing the accuracy of emergency triage.

Disclosed are a benzothiazepine compound, a preparation method therefor, and use thereof. Specifically disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound or the salt thereof has one or more of the following advantages: selective inhibition of HDAC6, stable metabolism, low toxicity, inhibition of tumor cells, protection of nerve cells, and having a relatively good in vivo antidepressant effect, and is expected to be used as a novel therapeutic agent for the clinical treatment of cancer or diseases of the nervous system.

The invention provides a nervous system clinical drainage stabilizing device which comprises a connecting rod, first vertical rods and second vertical rods are arranged at the two ends of the connecting rod respectively, and the outer surface walls of the two first vertical rods and the outer surface walls of the second vertical rods are each sleeved with a stabilizing assembly; wherein the stabilizing assembly comprises a lantern ring and a fixing block, the lantern ring is used for being connected with the first vertical rod and the second vertical rod, the fixing block is arranged on the outer side of the lantern ring, a telescopic column is arranged at the end, away from the lantern ring, of the fixing block, a spring ring is arranged in the fixing block and abuts against the telescopic column, and the spring ring is used for counteracting vibration generated by shaking of the drainage tube. A spring ring in the stabilizing assembly is used for buffering and fixing the drainage tube, vibration and external force borne by the drainage tube in the drainage process are effectively counteracted, and therefore the drainage tube is stably fixed, smooth drainage operation is guaranteed, and the risk of complications caused by shaking of the drainage tube is reduced. The safety and the effectiveness of clinical treatment of nervous system diseases are improved.

This invention provides the application of *Bifidobacterium animalis* subsp. lactis CP-9 in the preparation of compositions that promote neurodevelopment and alleviate cognitive impairment and nerve damage. This invention discovers that *Bifidobacterium animalis* subsp. lactis CP-9 can improve abnormal neurodevelopment, cognitive impairment, and nerve damage, and has a protective effect on the nervous system and overall health. This novel application expands the application scope of *Bifidobacterium animalis* subsp. lactis as a probiotic, and is of great significance for further exploring the functions of probiotics and developing probiotics with higher nutritional and health benefits. It also opens up new avenues and solutions for protecting nervous system health and preventing nervous system diseases through dietary strategies.